PittsburghV1, France, Analysis, bibRecord, 000445

Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database

Identifieur interne : 000445 ( France/Analysis ); précédent : 000444; suivant : 000446

Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database

Auteurs : Nadine J. Mccleary [États-Unis] ; Jeffrey A. Meyerhardt [États-Unis] ; Erin Green [États-Unis] ; Greg Yothers [États-Unis] ; Aimery De Gramont [France] ; Eric Van Cutsem [Belgique] ; Michael O'Connell [États-Unis] ; Christopher J. Twelves [Royaume-Uni] ; Leonard B. Saltz [États-Unis] ; Daniel G. Haller [États-Unis] ; Daniel J. Sargent [États-Unis]

Source :

Journal of clinical oncology [ 0732-183X ] ; 2013.

RBID : Pascal:13-0241735

Descripteurs français

Pascal (Inist)
- Cancer du côlon, Age, Efficacité traitement, Traitement adjuvant, Homme, Stade précoce, Stade avancé, Base de données, Cancérologie, Stade localement avancé.
Wicri :
- topic : Homme, Base de données.

English descriptors

KwdEn :
- Adjuvant treatment, Advanced stage, Age, Cancerology, Colon cancer, Database, Early stage, Human, Locally advanced stage, Treatment efficiency.

Abstract

Purpose Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) therapy are now standard. We examined the impact of age on colon cancer recurrence and mortality after adjuvant therapy with these newer options. Patients and Methods We analyzed 11,953 patients age < 70 and 2,575 age ≥ 70 years from seven adjuvant therapy trials comparing IV FU with oral fluoropyrimidines (capecitabine, uracil, or tegafur) or combinations of fluoropyrimidines with oxaliplatin or irinotecan in stage II/III colon cancer. End points were disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Results In three studies comparing oxaliplatin-based chemotherapy with IV FU, statistically significant interactions were not observed between treatment arm and age (P interaction = .09 for DFS, .05 for OS, and .36 for TTR), although the stratified point estimates suggested limited benefit from the addition of oxaliplatin in elderly patients (DFS hazard ratio [HR], 0.94; 95% CI, 0.78 to 1.13; OS HR, 1.04; 95% CI, 0.85 to 1.27). No significant interactions by age were detected with oral fluoropyrimidine therapy compared with IV FU; noninferiority was supported in both age populations. Conclusion Patients age ≥ 70 years seemed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting, although statistically, there was not a significant effect modification by age, whereas oral fluoropyrimidines retained their efficacy.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001E61
to stream PascalFrancis, to step Curation: 002A86
to stream PascalFrancis, to step Checkpoint: 001954
to stream Main, to step Merge: 007175
to stream Main, to step Curation: 006D53
to stream Main, to step Exploration: 006D53
to stream France, to step Extraction: 000445

Links to Exploration step

Pascal:13-0241735

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database</title>
<author><name sortKey="Mccleary, Nadine J" sort="Mccleary, Nadine J" uniqKey="Mccleary N" first="Nadine J." last="Mccleary">Nadine J. Mccleary</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Dana-Farber Cancer Institute</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Dana-Farber Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Meyerhardt, Jeffrey A" sort="Meyerhardt, Jeffrey A" uniqKey="Meyerhardt J" first="Jeffrey A." last="Meyerhardt">Jeffrey A. Meyerhardt</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Dana-Farber Cancer Institute</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Dana-Farber Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Green, Erin" sort="Green, Erin" uniqKey="Green E" first="Erin" last="Green">Erin Green</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Mayo Clinic</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Pittsburgh</s1>
<s2>Pittsburgh</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="De Gramont, Aimery" sort="De Gramont, Aimery" uniqKey="De Gramont A" first="Aimery" last="De Gramont">Aimery De Gramont</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hôpital Saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University Hospital Gasthuisberg</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>University Hospital Gasthuisberg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="O Connell, Michael" sort="O Connell, Michael" uniqKey="O Connell M" first="Michael" last="O'Connell">Michael O'Connell</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Mayo Clinic</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Twelves, Christopher J" sort="Twelves, Christopher J" uniqKey="Twelves C" first="Christopher J." last="Twelves">Christopher J. Twelves</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>University of Leeds and St James's Institute of Oncology</s1>
<s2>Leeds</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>University of Leeds and St James's Institute of Oncology</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B." last="Saltz">Leonard B. Saltz</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Memorial Sloan-Kettering Hospital</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Memorial Sloan-Kettering Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Haller, Daniel G" sort="Haller, Daniel G" uniqKey="Haller D" first="Daniel G." last="Haller">Daniel G. Haller</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Pennsylvania</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Pennsylvania</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Mayo Clinic</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0241735</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0241735 INIST</idno>
<idno type="RBID">Pascal:13-0241735</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E61</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002A86</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001954</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001954</idno>
<idno type="wicri:doubleKey">0732-183X:2013:Mccleary N:impact:of:age</idno>
<idno type="wicri:Area/Main/Merge">007175</idno>
<idno type="wicri:Area/Main/Curation">006D53</idno>
<idno type="wicri:Area/Main/Exploration">006D53</idno>
<idno type="wicri:Area/France/Extraction">000445</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database</title>
<author><name sortKey="Mccleary, Nadine J" sort="Mccleary, Nadine J" uniqKey="Mccleary N" first="Nadine J." last="Mccleary">Nadine J. Mccleary</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Dana-Farber Cancer Institute</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Dana-Farber Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Meyerhardt, Jeffrey A" sort="Meyerhardt, Jeffrey A" uniqKey="Meyerhardt J" first="Jeffrey A." last="Meyerhardt">Jeffrey A. Meyerhardt</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Dana-Farber Cancer Institute</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Dana-Farber Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Green, Erin" sort="Green, Erin" uniqKey="Green E" first="Erin" last="Green">Erin Green</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Mayo Clinic</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Pittsburgh</s1>
<s2>Pittsburgh</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="De Gramont, Aimery" sort="De Gramont, Aimery" uniqKey="De Gramont A" first="Aimery" last="De Gramont">Aimery De Gramont</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hôpital Saint Antoine</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University Hospital Gasthuisberg</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>University Hospital Gasthuisberg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="O Connell, Michael" sort="O Connell, Michael" uniqKey="O Connell M" first="Michael" last="O'Connell">Michael O'Connell</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Mayo Clinic</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Twelves, Christopher J" sort="Twelves, Christopher J" uniqKey="Twelves C" first="Christopher J." last="Twelves">Christopher J. Twelves</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>University of Leeds and St James's Institute of Oncology</s1>
<s2>Leeds</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>University of Leeds and St James's Institute of Oncology</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B." last="Saltz">Leonard B. Saltz</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Memorial Sloan-Kettering Hospital</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Memorial Sloan-Kettering Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Haller, Daniel G" sort="Haller, Daniel G" uniqKey="Haller D" first="Daniel G." last="Haller">Daniel G. Haller</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Pennsylvania</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Pennsylvania</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Mayo Clinic</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term>
<term>Advanced stage</term>
<term>Age</term>
<term>Cancerology</term>
<term>Colon cancer</term>
<term>Database</term>
<term>Early stage</term>
<term>Human</term>
<term>Locally advanced stage</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cancer du côlon</term>
<term>Age</term>
<term>Efficacité traitement</term>
<term>Traitement adjuvant</term>
<term>Homme</term>
<term>Stade précoce</term>
<term>Stade avancé</term>
<term>Base de données</term>
<term>Cancérologie</term>
<term>Stade localement avancé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Base de données</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) therapy are now standard. We examined the impact of age on colon cancer recurrence and mortality after adjuvant therapy with these newer options. Patients and Methods We analyzed 11,953 patients age < 70 and 2,575 age ≥ 70 years from seven adjuvant therapy trials comparing IV FU with oral fluoropyrimidines (capecitabine, uracil, or tegafur) or combinations of fluoropyrimidines with oxaliplatin or irinotecan in stage II/III colon cancer. End points were disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Results In three studies comparing oxaliplatin-based chemotherapy with IV FU, statistically significant interactions were not observed between treatment arm and age (P interaction = .09 for DFS, .05 for OS, and .36 for TTR), although the stratified point estimates suggested limited benefit from the addition of oxaliplatin in elderly patients (DFS hazard ratio [HR], 0.94; 95% CI, 0.78 to 1.13; OS HR, 1.04; 95% CI, 0.85 to 1.27). No significant interactions by age were detected with oral fluoropyrimidine therapy compared with IV FU; noninferiority was supported in both age populations. Conclusion Patients age ≥ 70 years seemed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting, although statistically, there was not a significant effect modification by age, whereas oral fluoropyrimidines retained their efficacy.</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
<li>France</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
<li>Pittsburgh</li>
</settlement>
<orgName><li>Université de Pittsburgh</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Mccleary, Nadine J" sort="Mccleary, Nadine J" uniqKey="Mccleary N" first="Nadine J." last="Mccleary">Nadine J. Mccleary</name>
</noRegion>
<name sortKey="Green, Erin" sort="Green, Erin" uniqKey="Green E" first="Erin" last="Green">Erin Green</name>
<name sortKey="Haller, Daniel G" sort="Haller, Daniel G" uniqKey="Haller D" first="Daniel G." last="Haller">Daniel G. Haller</name>
<name sortKey="Meyerhardt, Jeffrey A" sort="Meyerhardt, Jeffrey A" uniqKey="Meyerhardt J" first="Jeffrey A." last="Meyerhardt">Jeffrey A. Meyerhardt</name>
<name sortKey="O Connell, Michael" sort="O Connell, Michael" uniqKey="O Connell M" first="Michael" last="O'Connell">Michael O'Connell</name>
<name sortKey="Saltz, Leonard B" sort="Saltz, Leonard B" uniqKey="Saltz L" first="Leonard B." last="Saltz">Leonard B. Saltz</name>
<name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name>
<name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="De Gramont, Aimery" sort="De Gramont, Aimery" uniqKey="De Gramont A" first="Aimery" last="De Gramont">Aimery De Gramont</name>
</region>
</country>
<country name="Belgique"><noRegion><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
</noRegion>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Twelves, Christopher J" sort="Twelves, Christopher J" uniqKey="Twelves C" first="Christopher J." last="Twelves">Christopher J. Twelves</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000445 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000445 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:13-0241735
   |texte=   Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database

Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri